Author

C. J. A. Duncan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

C. F. Hatton· 2 shared F. Gothe· 2 shared S. Hambleton· 2 shared A. C. M. Khan· 1 shared A. I. Gardner· 1 shared A. T. Hanrath· 1 shared B. J. Thompson· 1 shared B. Verdon· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

C. F. Hatton

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Type I interferons govern Zika virus resistance of human macrophages and microglia

A. T. Hanrath, C. F. Hatton, F. Gothe, C. Browne, J. Vowles, P. Leary, S. J. Cockell, S. A. Cowley, W. S. James, S. Hambleton, C. J. A. Duncan

This study shows that type I interferons restrict Zika virus replication in macrophages and microglia, and their suppression increases viral replication and cell damage.

bioRxiv · Mar 9, 2022 · PreprintCell Biology

Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2

C. F. Hatton, R. A. Botting, M. E. Duenas, I. J. Haq, B. Verdon, B. J. Thompson, J. Stremenova Spegarova, F. Gothe, E. A. Stephenson, A. I. Gardner, S. Murphy, J. Scott, J. P. Garnett, S. Carrie, J. Powell, , C. J. A. Duncan

This study shows that delayed type I and III interferon responses in nasal epithelial cells allow SARS-CoV-2 replication, but pre-infection IFN treatment restricts virus and preserves barrier integrity.

bioRxiv · Feb 17, 2021Immunology